ANCA Vasculitis and the Complement System, Part 1: The Mouse’s Tale
Healio Rheuminations
English - February 03, 2021 15:39 - 31 minutes - 25.6 MB - ★★★★★ - 72 ratingsMedicine Health & Fitness arthritis autoimmune lupus medicine rheumatoid rheumatology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
This episode walks us through the initial research that paved the way for a game changing therapeutic in ANCA vasculitis, as well as the story of how host Adam J. Brown, MD, finally learned how to spell complement.
Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.
Intro :10 Welcome :21 Today’s episode :24 So how did we get there? 4:18 How do we start teasing apart the effect of the complement in ANCA vasculitis? 8:13 Discussing and simplifying the mouse model 9:00 Quickly reviewing the complement cascade 12:06Brought to you by GSK. Consider the long-term impact of disease activity flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com.
Taking the puzzle pieces away in the mouse model 17:04 What about the next steps? 22:05 What happens when you block C5a? 25:12 CCX168: Summing up the mouse tale 28:44 In the next episode 30:20 Thanks for listening 30:46Disclosures: Brown reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to Dr. Brown at [email protected]. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Brilland B, et al. Autoimmun Rev. 2020;19:102424.
Freeley SJ, et al. J Pathol 2016;240:61-71.
Haas M, Eustace JA. Kidney Int 2004;65:2145-2152.
Huugen D, et al. Kidney Int 2007;71:646-654.
Marder SR, et al. Arg. J Immunol. 1985;134:3325-3331.
Schreiber A, et al. J Am Soc Nephrol. 2009;20:289-298.
Xiao H, et al. Am J Pathol. 2007;170:52-64.